Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

DNA repair and personalized breast cancer therapy.

Li SX, Sjolund A, Harris L, Sweasy JB.

Environ Mol Mutagen. 2010 Oct-Dec;51(8-9):897-908. doi: 10.1002/em.20606. Review.

2.

Personalized therapy for breast cancer: a dream or a reality?

Zardavas D, Pugliano L, Piccart M.

Future Oncol. 2013 Aug;9(8):1105-19. doi: 10.2217/fon.13.57.

PMID:
23902243
3.

Personalized medicine: present and future of breast cancer management.

Sabatier R, Gonçalves A, Bertucci F.

Crit Rev Oncol Hematol. 2014 Sep;91(3):223-33. doi: 10.1016/j.critrevonc.2014.03.002. Epub 2014 Mar 26. Review.

PMID:
24725667
4.

Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.

Nowsheen S, Whitley AC, Yang ES.

Curr Mol Med. 2012 Jul 1;12(6):788-803. Review.

PMID:
22292444
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
6.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.

Oncogene. 1998 Oct 29;17(17):2235-49.

7.

Epigenetic inactivation of DNA repair in breast cancer.

Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG.

Cancer Lett. 2014 Jan 28;342(2):213-22. doi: 10.1016/j.canlet.2012.05.015. Epub 2012 May 23. Review.

PMID:
22634493
8.

Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Rivenbark AG, O'Connor SM, Coleman WB.

Am J Pathol. 2013 Oct;183(4):1113-24. doi: 10.1016/j.ajpath.2013.08.002. Epub 2013 Aug 27. Review.

9.

Novel treatment approaches for triple-negative breast cancer.

Telli ML, Ford JM.

Clin Breast Cancer. 2010;10 Suppl 1:E16-22. doi: 10.3816/CBC.2010.s.003. Review.

PMID:
20587403
10.

In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time?

Dent RA, Bristow RG.

J Clin Oncol. 2011 Jun 1;29(16):2130-2. doi: 10.1200/JCO.2010.34.1990. Epub 2011 Apr 25. No abstract available.

11.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
12.

Genetic heterogeneity in breast cancer: the road to personalized medicine?

Baird RD, Caldas C.

BMC Med. 2013 Jun 18;11:151. doi: 10.1186/1741-7015-11-151. Review.

13.

Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.

Silva SN, Tomar M, Paulo C, Gomes BC, Azevedo AP, Teixeira V, Pina JE, Rueff J, Gaspar JF.

Cancer Epidemiol. 2010 Feb;34(1):85-92. doi: 10.1016/j.canep.2009.11.002. Epub 2009 Dec 9.

PMID:
20004634
14.

Epigenetic modifications in breast cancer and their role in personalized medicine.

Stefansson OA, Esteller M.

Am J Pathol. 2013 Oct;183(4):1052-63. doi: 10.1016/j.ajpath.2013.04.033. Epub 2013 Jul 27. Review.

15.

Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.

Goldhirsch A.

Breast. 2013 Aug;22 Suppl 2:S3-7. doi: 10.1016/j.breast.2013.07.001. Review.

PMID:
24074788
16.

Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.

Roukos DH.

Pharmacogenomics J. 2011 Apr;11(2):81-92. doi: 10.1038/tpj.2010.81. Epub 2010 Oct 26. Review.

PMID:
20975737
17.

Personalized medicine for metastatic breast cancer.

Chen TW, Bedard PL.

Curr Opin Oncol. 2013 Nov;25(6):615-24. doi: 10.1097/CCO.0000000000000015. Review.

PMID:
24097103
18.

[Breast cancer. Individualized therapy concepts].

Harbeck N, Wuerstlein R.

Internist (Berl). 2013 Feb;54(2):194-9. doi: 10.1007/s00108-012-3156-9. German.

PMID:
23371261
19.

Update on clinical trials: genetic targets in breast cancer.

Lim B, Cream LV, Harvey HA.

Adv Exp Med Biol. 2013;779:35-54. doi: 10.1007/978-1-4614-6176-0_2. Review.

PMID:
23288634
20.

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A.

Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Review.

PMID:
22178455
Items per page

Supplemental Content

Write to the Help Desk